Management of illness through medication has entered an era of rapid growth. A variety of means by which drugs are delivered to the human body for the therapy such as tablets, capsules, injections, aerosols, creams, ointments, suppositories, liquids etc. are referred as a conventional drug formulations. Among many pharmaceutical dosage forms, continuous intravenous infusion at preprogrammed rate has been recognized as a superior mode of drug delivery. At present, the most common form of delivery of drugs is the oral route. It has the notable advantage of easy administration.
2. Contents:-
Introduction to TDDS’s
Basic Components of TDDS’s
Factors of TDDS
Penetration Enhancements
Percutaneous Absorption
Approaches used in TDDS’s
Production of TDDS’s
Model Drug Selection Criteria
Evaluation of TDDS
06/04/16SAGAR KISHOR SAVALE2
3. A] Introduction to TDDS’s-
Management of illness through medication has entered an era of rapid
growth. A variety of means by which drugs are delivered to the human body
for the therapy such as tablets, capsules, injections, aerosols, creams,
ointments, suppositories, liquids etc. are referred as a conventional drug
formulations.
Among many pharmaceutical dosage forms, continuous intravenous
infusion at preprogrammed rate has been recognized as a superior mode of
drug delivery.
At present, the most common form of delivery of drugs is the oral route.
It has the notable advantage of easy administration.
Contd...
06/04/16SAGAR KISHOR SAVALE3
4. But these delivery systems having some Drawbacks-
Oral- poor bioavailability
hepatic metabolism (first pass)
tendency to produce rapid blood level spikes
need of high and/or frequent dosing
Intravenous- These mode of drug delivery entails certain risks
and therefore necessities hospitalization of the patients and close
medical supervision of the medication.
To overcome these difficulties there is a need for the
development of new drug delivery system which will improve the
therapeutic efficacy and safety of drugs by more precisely.
Contd...
06/04/16SAGAR KISHOR SAVALE4
5. The integument as an organ
The integument as an organ,
and is an
alternative name for skin.
The integumentary system
includes the skin and the skin
derivatives hair, nails, and
glands.
06/04/16SAGAR KISHOR SAVALE5
6. The Integument
Is the largest system of the body
16% of body weight,
1.5 to 2m2
in area,
The integument is made up of two parts:
1. Cutaneous membrane
a. Epidermis– Superficial epithelium
b. Dermis – underlying CT with blood supply
2. Accessory structures
a. Hair
b. Nails
c. Exocrine Glands
06/04/16SAGAR KISHOR SAVALE6
7. Protection
First line of defense against
Bacteria
Viruses
Protects underlying structures from
Ultraviolet (UV) radiation
Dehydration
Vitamin D production
Needed for calcium absorption
Sensation
Sensory receptors
06/04/16SAGAR KISHOR SAVALE7
8. Body temperature regulation
If too hot
Dermal blood vessels dilate
Vessels carry more blood to surface so heat can escape
If too cold
Dermal blood vessels constrict
Prevents heat from escaping
Excretion
Small amounts of waste products are lost through perspiration
06/04/16SAGAR KISHOR SAVALE8
9. Understanding how the skin can function in these many ways starts
with understanding the structure of the 3 layers of skin
The Epidermis
Epithelial tissue
Dermis
Dense connective tissue proper – irregular
Hypodermis
Subcutaneous tissue- loose connective tissue proper and adipose
tissue
06/04/16SAGAR KISHOR SAVALE9
14. The Epidermis
Is a vascular stratified squamous epithelium
Nutrients and oxygen diffuse from capillaries in the dermis
Cells of the Epidermis
Keratinocytes
Contain large amounts of keratin
Are the most abundant cells in the epidermis
06/04/16SAGAR KISHOR SAVALE14
16. The structural relationship and
interface between the epidermis
and underlying dermis. The
proportions of the various layers
differ with the location sampled.
Dermis
Epidermis
Epidermal
ridge
Dermal
papilla
06/04/16SAGAR KISHOR SAVALE16
17. Thin Skin
Covers most of the body
Has four layers of keratinocytes
Thick Skin
Covers the palms of the hands and soles of the feet
Has five layers of keratinocytes
06/04/16SAGAR KISHOR SAVALE17
18. Structures of the Epidermis
The five strata of keratinocytes in thick skin
From basal lamina to free surface
1. Stratum basale
2. Stratum spinosum
3. Stratum granulosum
4. Stratum lucidum
5. Stratum corneum
06/04/16SAGAR KISHOR SAVALE18
20. Stratum Basale
Is attached to basement membrane by hemidesmosomes
Forms a strong bond between epidermis and dermis
Forms epidermal ridges (e.g., fingerprints)
Dermal papillae (tiny mounds)
Increase the area of basement membrane
Strengthen attachment between epidermis and dermis
Has many basal cells or germinative cells
06/04/16SAGAR KISHOR SAVALE20
21. Thick skin SEM × 25
Epidermal
ridge
Pores of sweat
gland ducts
Epidermal ridges
06/04/16SAGAR KISHOR SAVALE21
22. Stratum Spinosum — the “spiny layer”
Produced by division of stratum basale
Eight to ten layers of keratinocytes bound by desmosomes
Cells shrink until cytoskeletons stick out (spiny)
Continue to divide, increasing thickness of epithelium
Contain dendritic (Langerhans) cells, active in immune response
06/04/16SAGAR KISHOR SAVALE22
23. Stratum Granulosum — the “grainy layer”
Stops dividing, starts producing
Keratin
A tough, fibrous protein
Makes up hair and nails
Keratohyalin
Dense granules
Cross-link keratin fibers
06/04/16SAGAR KISHOR SAVALE23
24. Stratum Lucidum — the “clear layer”
Found only in thick skin
Covers stratum granulosum
Stratum Corneum — the “horn layer”
Exposed surface of skin
15 to 30 layers of keratinized cells
Water resistant
Shed and replaced every 2 weeks
06/04/16SAGAR KISHOR SAVALE24
25. The Dermis
Located between epidermis and
subcutaneous layer
Anchors epidermal accessory
structures (hair follicles, sweat
glands)
Two components
1. Outer papillary layer
2. Deep reticular layer Dermis
06/04/16SAGAR KISHOR SAVALE25
26. The Papillary Layer
Consists of areolar tissue
Contains smaller capillaries, lymphatics, and sensory neurons
Has dermal papillae projecting between epidermal ridges
The Reticular Layer
Consists of dense irregular connective tissue
Contains larger blood vessels, lymphatic vessels, and nerve fibers
Contains collagen and elastic fibers
Contains connective tissue proper
06/04/16SAGAR KISHOR SAVALE26
27. An inflammation of the papillary layer
Caused by
infection, radiation, mechanical irritation, or chemicals (e.g., poison
ivy)
Characterized by
itch or pain
Characteristics
Strong, due to collagen fibers
Elastic, due to elastic fibers
Flexible
06/04/16SAGAR KISHOR SAVALE27
29. The Hypodermis (Subcutaneous Layer)
Lies below the integument
Stabilizes the skin
Allows separate movement
Made of elastic areolar and adipose tissues
Connected to the reticular layer of integument by connective
tissue fibers
Deposits of Subcutaneous Fat
Distribution patterns determined by hormones
Reduced by cosmetic liposuction (lipoplasty)
06/04/16SAGAR KISHOR SAVALE29
32. One of the methods most often utilized has been transdermal
delivery - meaning transport of therapeutic substances through
the skin for systemic effect in the form of patches that deliver
drugs for systemic effects at a predetermined and controlled rate.
Definition- When the aim is to deliver drugs through skin in
a predetermined & controlled release fashion, it is known
transdermal drug delivery system.
It is a polymeric drug delivery system which contains drug
either in a reservoir with a rate – controlling membrane or
dispersed in polymer matrix.
Contd...
06/04/16SAGAR KISHOR SAVALE32
33. Comparison between IV, Oral and TDDs:-
I V Oral TDD
Reduced Liver First
pass effect
Yes No Yes
Constant Drug Levels Yes No Yes
Self-administration No Yes Yes
Unrestricted Patient
Activity
No Yes Yes
Non-invasive No Yes Yes
Contd...
06/04/16SAGAR KISHOR SAVALE33
34. Advantages of Transdermal system:-
Dosage intervals not limited by gastric transit time.
Avoid the first- pass effect.
Noninvasive.
Allows effective use of drug with short biological half- life.
Drugs with narrow therapeutic indices can be safely administered.
Drug therapy may be terminated rapidly by removal of the application from the
surface of the skin.
Self administration is possible.
Single application has capacity for multi-day therapy, thereby improving patient
compliance.
Easy to prepare and easy to transport.
Contd...
06/04/16SAGAR KISHOR SAVALE34
35. Disadvantages of Transdermal system:-
Only potent drugs are suitable Candidate.
Unsuitable for drugs that irritate or sensitize the skin.
These systems include variation in absorption efficiency at different
sites of skin
Maintaining contact between device & skin can be problem.
Barrier function of skin changes from one site to another on same
person, from person to person & with age.
Some Patients develop contact dermatitis at the site of application.
Contd...
06/04/16SAGAR KISHOR SAVALE35
36. These Route is Unsuitable when:-
Drug dose is large.
Drug has large molecular size.
Drug is skin sensitizing and irritating.
Drug is highly lipophilic or hydrophilic.
06/04/16SAGAR KISHOR SAVALE36
37. B] Basic Components Of Transdermal System:-
Polymer matrix / Drug reservoir
Drug
Penetration enhancers
Pressure sensitive adhesive (PSA)
Backing laminates
Release liner
Other excipients like plasticizers and solvents
06/04/16SAGAR KISHOR SAVALE37
38. Polymer matrix / Drug reservoir:-
Control the release of the drug.
Prepared by dispersion.
Should have biocompatibility and chemical compatibility.
Natural Polymer Synthetic Elastomer Synthetic Polymer
Gelatin Neoprene Polyethylene
Gum Arabic Silicone rubber Polystyrene
Starch Butyl rubber PVC
Shellac Chloroprene PVP
zein Polysiloxane Polyster
Contd...
06/04/16SAGAR KISHOR SAVALE38
39. Drug:-
The foremost requirement of TDDS is that the drug possesses the right mix
of physicochemical and biological properties.
Biological properties-
Therapeutic Index
Biological half life
Skin toxicity
Physicochemical properties-
Mol. Wt
Partition coefficient
Drug stability
Melting point
Contd...
06/04/16SAGAR KISHOR SAVALE39
40. Penetration Enhancers:-
Two types of principles have been employed to increase drug permeation (and
drug absorption) through skin: chemical and physical.
Chemical enhancers-
Substance exist which temporarily diminish the impermeability of the
skin, known also as accelerants or sorption promoters.
Examples-Sulphoxides and similar chemicals, Azone, Pyrrolidones, Fatty acids,
Essential oils, terpenes, terpenoids, Oxazolidodienes and Urea.
Physical enhancers-
Physical enhancement technologies have taken off where the limitations
of chemical enhancement have been reached.
Methodologies involved in the physical transdermal delivery including:
•Electrically-based techniques: iontophoresis, electroporation, ultrasound,
photomechanical wave,
•Structure-based techniques: microneedles, and
•Velocity-based techniques: jet-propulsion
Contd...
06/04/16SAGAR KISHOR SAVALE40
41. Pressure Sensitive Adhesives (PSA):-
A PSA is a material that helps in maintaining an intimate contact between
transdermal system and the skin surface.
It can be positioned on the face of the device
Some widely used pressure sensitive adhesives are-
Polyisobutylene
Polyacrylates
Silicones
Contd...
1506/04/16SAGAR KISHOR SAVALE41
42. Backing Laminate:-
Hold and protect the drug reservoir from exposure to atmosphere.
Avoid loss of drug
Accept printing
High flexibility
Good oxygen transmission and a high moisture vapor transmission rate
Examples- vinyl, polyethylene and polyester films.
Release Liner:-
During storage the patch is covered by a protective liner that is removed and
discharged immediately before the application of the patch to skin.
Part of primary packaging
Base layer -Non-occlusive (e.g. paper fabric) or occlusive (e.g. polyethylene,
polyvinylchloride).
Release coating layer- silicon or Teflon.
Contd...
06/04/16SAGAR KISHOR SAVALE42
43. Other Excipients:-
Various solvents used to prepare drug reservoir
Ex- chloroform, methanol, acetone, isopropanol and dichloromethane.
Plasticizers are also added to provide plasticity to the transdermal
patch.
Ex- dibutylpthalate, triethylcitrate, polyethylene glycol and propylene
glycol
06/04/16SAGAR KISHOR SAVALE43
46. C] Penetration Enhancement:-
Skin structure as it relates to drug penetration:-
The skin is a multilayered organ, complex in structure and function. It is
composed of-
Outer epidermis (outermost layered called STRATUM CORNEUM)
Viable epidermis (stratum lucidum, stratum granulosum, stratum spinosum and
stratum germinotive)
Dermis
Contd...
06/04/16SAGAR KISHOR SAVALE46
47. Enhancers:-
Three pathways for drug penetration through the skin-
Polar (cause protein conformational change or solvent swelling).
Non-polar (alter the rigidity of lipid structure which substantially increase
diffusion).
Polar/non-polar (altering the multilaminated pathway for penetrants).
Contd...
06/04/16SAGAR KISHOR SAVALE47
49. Classification Of Penetration Enhancement
Chemical Physical
1. Sulphoxides and similar
chemicals
2. Azone
3. Pyrrolidones
4. Fatty acids
5. Essential oils, terpenes
and terpenoids
6. Oxazolidodienes
7. Urea
A] Electrically based techniques-
1. Iontophoresis
2. Electroporation
3. Ultrasound (sonophoresis)
4. Photochemical waves
5. Laser Ablation
6. Combination of electrically based physical
enhancement technique and chemical enhancers.
B] Structured based technique-
1. Micro needles
C] Velocity based technique-
1. Jet-propelled particles
Contd...
06/04/16SAGAR KISHOR SAVALE49
50. Chemical Penetration Enhancement:-
Ideal characteristics of chemical penetration enhancers
Non-toxic, non-irritating and non-allergenic
The activity and duration of effect should be both predictable and
reproducible.
No pharmacological activity within the body.
Unidirectional
Barrier properties should return to normal.
Cosmetically acceptable with an appropriate skin feel.
Mechanism of chemical penetration enhancement:-
Disruption of the highly ordered structure of stratum corneum lipid.
Interaction with intercellular protein.
Improved partition of the drug, co enhancer or solvent into the stratum
corneum.
06/04/16SAGAR KISHOR SAVALE50
51. 1. Sulphoxides and similar chemicals:-
Aprotic solvent, colourless, odourless and hydroscopic
It is known as ‘Universal Solvent’ for TDDs.
The effect is concentration-dependant (›60% )
Cause erythema, denaturing of skin, burning sensation.
Ex- showing a 12-fold increase in the flux of caffeine permeating across a
DMF-treated human skin, but it also shows irreversible damage to skin.
2. Azone:-
Azone (1-dodecylazacycloheptan-2-one or laurocapran)
Colourless, odourless liquid with a melting point of -7 ºC
Smooth, oily but yet non-greasyfeel.
Soluble in most of organic solvent.
Effect showing in 0.1-5% (more often between 1-3%)
Contd...
06/04/16SAGAR KISHOR SAVALE51
52. 3. Pyrrolidones:-
Used as permeation enhancers for numerous molecules including hydrophilic (e.g.
mannitol and 5-flurouracil) and lipophilic (progesterone and hydrocortisone) permeants.
Ex-N-methyl-2 pyrolidone was employed with limited success as a penetration enhancer
for captopril when formulated in a matrix-type transdermal patch.
4. Fatty acids:-
Percutaneous absorption can be increased by long-chain fatty acids such as oleic acid.
Ex- Oleic acid increase the flux 28 fold of salicylic acid and 56 of 5-flourouracil.
5. Essential oils, terpenes and terpenoids:-
It is used as medicinal use as well as flavoring agent and fragrance agent.
Ex- Chenopodium found to be effective penetration enhancers for
5-flouorouracil transversing human skin.
Contd...
06/04/16SAGAR KISHOR SAVALE52
53. 6. Oxazolidinones:-
Potential for use in many cosmetic and personal care product
formulations.
It having ability to localize co-administered drug in skin layers, resulting
in low systemic permeation.
Ex- 4-decyloxazolidin-2-one -localize the delivery of retinoic acid and
diclofenac sodium in skin layers.
7. Urea
Cyclic urea permeation enhancers are biodegradable and non-toxic
molecules.
Enhancement mechanism by lipid disruption mechanism.
06/04/16SAGAR KISHOR SAVALE53
54. Physical Penetration Enhancement:-
1. Iontophoresis:-
It acts by repulsion effect between charged electrode and solute(drug reservoir)
Applied electric current of 0.5mA/cm2
Low M.W (‹500 Da)
Ex- Lidocaine, metoclopramide plus hydrocortisone, vincristine etc,.
Contd...
06/04/16SAGAR KISHOR SAVALE54
55. 2. Electroporation:-
Process involves the application of large transmembrane voltages caused by
electrical pulses (10 s–100ms).μ
It cause formation of transient pores in the membrane that allow the passage for
drug.
Induce steady-state transport through skin with in minute.
Controllable through manipulation of electrical pulse.
Contd...
06/04/16SAGAR KISHOR SAVALE55
56. 3. Ultrasound (or sonophoresis):-
Traditionally associated with physiotherapy, sports medicine and medical
imaging than TDDs.
It produces physical air pressure above topical skin.
Deliver drug in low frequency range 20 kHz. (less than used in physiotherapy
1MHz)
Contd...
06/04/16SAGAR KISHOR SAVALE56
57. 4. Photochemical Waves:-
It also known as laser generated stress
waves
PWs are the pressure pulses produced
by ablation of a material target.
It is not much more attention.
5. Laser Ablation:-
The use of lasers to remove the stratum corneum barrier by controlled ablation.
It is reported that use of LAs on pig Stratum corneum- hydrocortisone.
6. Combination of electrically based physical enhancement technique
and chemical enhancers.
Contd...
06/04/16SAGAR KISHOR SAVALE57
58. Structured- based technique:-
Microneedle:-
They create a physical pathway through the upper epidermis to increase skin
permeability.
Made up of silicon
Silicon needles individual measuring about 150 m in length and 80 m baseμ μ
diameter and fabricated on array of 3x3 mm (400 needles).
Contd...
06/04/16SAGAR KISHOR SAVALE58
59. Velocity based technique-
Jet-propelled particles:-
It propel the drug into the skin.
High velocity jet (100m/s) of compressed gas (helium).
06/04/16SAGAR KISHOR SAVALE59
60. 06/04/16SAGAR KISHOR SAVALE60
Absorbed in Surface of sebum
TransdermalTransdermal Trans follicularTrans follicular
Intracellular Pathway Intercellular Pathway
Stratum Corneum
Pilosebaceous Unit Eccrine Gland
Sebaceous GlandHair Follicles
Dermis
Microcirculation
Viable Epidermis
Percutaneous absorption
Drug can releases
from dosage from
62. 06/04/16SAGAR KISHOR SAVALE62
Generally, drug absorption into the skin occurs by passive diffusion.
The rate of drug transport across the stratum corneum follows fick’s
first law of diffusion.
dm/dt = J = d a k/h
Where,
dm / dt = J = rate of diffusion / study state flux.
d = diffusion coefficient.
a = surface area of membrane.
k = partial coefficient between the stratum corneum and the vehicle.
h = diffusional path length / membrane thickness.
63. 06/04/16SAGAR KISHOR SAVALE63
In other words, the rate of drug transport depends not only on its
aqueous solubility,
But is also directly proportional to its oil/water partition
coefficient, its concentration in the formulation vehicle, and the
surface area of the skin to which it is exposed;
It is inversely proportional to the thickness of the stratum
corneum.
65. D] Approaches Used in TDDs:-
Approaches
A) According to drug release
mechanisms:-
1. Matrix-diffusion controlled TDDS’s
2. Membrane-permeation controlled
TDDS’s
3. Microreservoir type or Micro sealed
dissolution controlled TDDS’s
4. Adhesive dispersion type TDDS’s
B) According to rate
controlling step:-
1. Those control the rate
of drug delivery to skin.
2. Those allow the skin to
control the rate of drug
absorption.
C) According to
polymer:-
1. Hydrophilic or
hydro gel system
2. Hydrophobic or
occlusion system
Contd...
06/04/16SAGAR KISHOR SAVALE65
66. a] According to drug release mechanisms:-
1. Matrix-diffusion controlled TDDS’s:-
Drug Reservoir- Dispersing drug particles in a hydrophilic or lipophilic
polymer matrix which is accomplished by:
Homogeneously mixing of grounded particles
Liquid
polymer
Highly viscous
base polymer
Blending of particle with
rubbery polymer
Molded in medicated disc
Also by dissolving Drug and Polymer in common solvent solvent
evaporation method
Pasted on occlusive base plate
Impermeable plastic membrane
Contd...
06/04/16SAGAR KISHOR SAVALE66
68. 2. Membrane-permeation controlled TDDS’s:-
Drug reservoir- Grounded Drug particles
Dispersed in solid polymer
matrix
Suspended in viscous liquid medium
(silicon)
Rate-controlling polymeric membrane (EVA)
Adhesive polymer (silicon, PA)
The release of Drug from the system by rate- controlling polymer.
Achieved by Polymer composition, permeability coefficient and thickness.
Contd...
06/04/16SAGAR KISHOR SAVALE68
69. Examples:-
•Nitroglycerine –releasing transdermal system (once a day for angina pectoris)
•Scopolamine-releasing transdermal system (72hrs for motion sickness)
•Clonidine-releasing transdermal system (7 days for hypertension)
The constant release of the drug is the major advantages of
these approaches.
Contd...
06/04/16SAGAR KISHOR SAVALE69
70. 3. Microreservoir type or Micro sealed dissolution controlled
TDDS’s:-
It can be considered as a combination of the reservoir and matrix diffusion type
drug delivery systems.
Drug reservoir:- Drug particle
Drug suspensionDispersing in a lipophilic polymer (silicon) by high
dispersion technique
Spheres of DR
Medicated disc
Surrounded by adhesive film
Aqueous solution (water-soluble liq.
Polymer)
Contd...
06/04/16SAGAR KISHOR SAVALE70
71. Example- Nitrodisc for angina pectoris (0.5mg/cm2
OD)
The release of drug from this system can follow either a partition control
or matrix diffusion-control process.
Contd...
06/04/16SAGAR KISHOR SAVALE71
72. 4. Adhesive dispersion type TDDS’s:-
Simple form of Membrane-permeation controlled TDDs.
Drug reservoir:- Drug particle Dispersed in adhesive polymer (poly
(isobutylene) or poly(acrylate) )
Medicated disc (solvent
casting or hot melt)
Impermeable film
Example-Isosorbide dinitrate,releasing TDDs for angina pectoris (OD)
Contd...
06/04/16SAGAR KISHOR SAVALE72
73. b] According to rate controlling step:-
Those they control the rate of drug delivery to the skin.
Potent, for maintaining MEC
Those that allow the skin to control the rate of drug absorption.
Having wide range of plasma drug concentration.
c] According to polymer:-
Hydrophilic or hydro gel system:-
Drug release by swelling mechanism.
Patch of these type absorb water from the skin.
Causes skin irritation & burning sensation.
Contd...
06/04/16SAGAR KISHOR SAVALE73
74. Hydrophobic or occlusion system:-
Prevent losing of water from the skin.
Swelling of Horny layer at skin surface.
Increases the temperature and resulting in increase in molecular motion &
skin permeation & decrease in protein network density.
Causes sweat retention syndrome, irritation reaction.
06/04/16SAGAR KISHOR SAVALE74
78. E] Model Drug Selection Criteria:-
Most drugs are not suitable candidate for Transdermal drug delivery for one or
more reason-
‘Easy to deliver’ drugs have already been commercialized into TDDs.
To date 10 drugs out of 100 have been commercialized into TDDs.
More than 35 patches spanning 13 molecules present in market.
For successfully developing a transdermal drug delivery system, the drug should
be chosen with great care.
The drug possesses the right mix of physicochemical and biological properties
for transdermal drug delivery.
Contd...
06/04/16SAGAR KISHOR SAVALE78
79. The following are some desirable properties of a drug for Selection of drug
for transdermal delivery:-
Biological Properties:-
Therapeutic Index:- Narrow therapeutic index
First-pass metabolism- drug which goes extensive to First-pass metabolism.
Biological Half Life- Short (10hrs or less)
Skin Toxicity- Should not irritant and sensitizing to skin.
Dose- less than 20mg/day.
Immunogenicity- Drug should not stimulate on immune reaction.
Contd...
06/04/16SAGAR KISHOR SAVALE79
80. Physicochemical Properties:-
Molecular Weight:- less than 500 Daltons.
Partition coefficient- Should have octanol-water partition coefficient
(LogP) value in range 1.0- 4.0 .
Drug Stability
Skin permeability coefficient- greater than 0.5x10 cm/hr.
Melting point- low (2000
F).
06/04/16SAGAR KISHOR SAVALE80
85. 06/04/16SAGAR KISHOR SAVALE85
Sr. No. Evaluation Parameters
1 Percentage of Moisture Absorption
2 Percentage of Moisture Loss
3 Thickness of Film
4 Weight Variation
5 Drug Content
6 In vitro drug release study
7 In vivo drug release study
8 Stability test
9 Sterility test
10 Tensile strength
11 Water Absorption test
86. 06/04/16SAGAR KISHOR SAVALE86
Physicochemical Evaluation of Transdermal Patches
Thickness - travelling microscope, dial/screw gauge,
micrometer
Weight variation – weigh 10 patches
Drug content – by suitable validated analytical method
Folding endurance – repeatedly folding at same point
until it break . The number of times it could be folded is
its folding endurance value.
87. 06/04/16SAGAR KISHOR SAVALE87
Content uniformity- 10 patches are selected and
content is determined for individual patches. If 9 out of
10 patches have content between 85% to 115% of the
specified value and one has content not less than 75% to
125% of the specified value, then Transdermal patches
pass the test of content uniformity. But if 3 patches have
content in the range of 75% to 125%, then additional 20
patches are tested for drug content. If these 20 patches
have range from 85% to 115%, then the Transdermal
patches pass the test.
Microscopic study- SEM
89. 06/04/16SAGAR KISHOR SAVALE89
Swellability-The degree of swelling (% S) was
calculated using the formula
S (%) = Wt – Wo/Wo x 100
Where S is percent swelling
Wt is the weight of patch at time t and W o is
the weight of patch at time zero
Surface pH-
Hardness-
Physical appearance
All the Transdermal patches were visually
inspected for color, clarity, flexibility, and
smoothness
90. 06/04/16SAGAR KISHOR SAVALE90
Flatness one strip is cut from the centre and two from
each side of patches. The length of each strip is
measured and variation in length is measured by
determining percent constriction. Zero percent
constriction is equivalent to 100 percent flatness.
% constriction =[(I1-I2)/I1]X100
I2 = Final length of each strip
I1 = Initial length of each strip
Percentage of moisture content
% Moisture content = Initial weight – Final weight X
100
Final weight
91. 06/04/16SAGAR KISHOR SAVALE91
Percentage of moisture uptake-
% moisture uptake = Final weight – Initial weight X 100
Initial weight
Water Vapor Transmission study-
WVT = W/ ST
W is the increase in weight in 24 h; S is area of
film exposed (cm2
); T is exposure time .
Tensile strength-
Tensile strength= F/a.b (1+L/l)
F is the force required to break; a is width of film; b is
thickness of film; L is length of film; l is elongation of film
at break point
92. 06/04/16SAGAR KISHOR SAVALE92
Peel Adhesion properties
Tack properties
I. Thumb tack test
II. Rolling ball test
III. Quick stick (Peel tack) test
IV. Probe tack test
Shear Strength
93. 06/04/16SAGAR KISHOR SAVALE93
Figure: 1 Peel Adhesion Test
In this test, the force required to remove an adhesive coating form a
test substrate is referred to as peel adhesion.
Molecular weight of adhesive polymer, the type and amount of
additives are the variables that determined the peel adhesion properties.
A single tape is applied to a stainless steel plate or a backing membrane
of choice and then tape is pulled from the substrate at a 180°C angle, and
the force required for tape removed is measured.
94. 06/04/16SAGAR KISHOR SAVALE94
It is the ability of the polymer to adhere to substrate with little contact
pressure. Tack is dependent on molecular weight and composition of
polymer as well as on the use of tackifying resins in polymer
The force required to remove thumb from adhesive is a measure
of tack.
This test measures the softness of a polymer.
95. 06/04/16SAGAR KISHOR SAVALE95 Figure: 2 Rolling ball tack test
In this test, stainless steel ball of 7/16 inches in diameter is released on
an inclined track so that, it rolls down and comes into contact with
horizontal, upward facing adhesive (Figure: 2).
The distance the ball travels along the adhesive provides the
measurement of tack, which is expressed in inch
96. 06/04/16SAGAR KISHOR SAVALE96
Figure: 3 Quick stick (peel-tack) test
In this test, the tape is pulled away from the substrate at 90ºC at a
speed of 12 inches/min. The peel force required breaking the bond
between adhesive and substrate is measured (Figure-3) and recorded
as tack value, which is expressed in ounces or grams per inch width .
97. 06/04/16SAGAR KISHOR SAVALE97
Figure: 4 Probe Tack test
In this test, the tip of a clean probe with a defined surface roughness is
brought into contact with adhesive, and when a bond is formed between
probe and adhesive. The subsequent removal of the probe mechanically
breaks it (Figure-4). The force required to pull the probe away from the
adhesive at fixed rate is recorded as tack and it is expressed in grams.
98. 06/04/16SAGAR KISHOR SAVALE98
Figure: 5 Shear strength properties
Shear strength is the measurement of the cohesive strength of an
adhesive polymer i.e. device should not slip on application determined by
measuring the time it takes to pull an adhesive coated tape off a stainless
plate.
101. 06/04/16SAGAR KISHOR SAVALE101
Comparison in In vitro and In vivo Transdermal
permeation rates
Permeation rates (mcg/cm2
/day)
In vitro In vivo
Drugs Delivery systems Hairless mouse Human cadaver
Nitroglycerin Nitro disc 435.6
- 713.0
Nitro dur 400.1 487.9 411.6
Transderm- nitro 349.2 461.5 427.9
Deponit 269.5
- 282.5
Estradiol Estraderm 9.6 6.5 5.0
Clonidine Catapres-TTS 68.9 49.2 38.9
102. 06/04/16SAGAR KISHOR SAVALE102
According to the International Conference on Harmonization (ICH)
guidelines by storing the TDDS samples at 40± 2°C and 75 ± 5% RH
for 6 months. The samples were withdrawn at 0, 30, 60, 90 and 180
days and analyzed for drug content by suitable analytical technique.
103. 06/04/16SAGAR KISHOR SAVALE103
Toxicological Evaluation-
a) Contact dermatitis
1. contact irritant dermatitis
2. ten day primary irritation test
3. twenty one day irritation test
4. laser doppler
5. evaporative water loss measurement
6. contact allergic dermatitis
b) Growth of microorganisms
1. localized superficial infections
2. miliaria(prickly heat)
104. 06/04/16SAGAR KISHOR SAVALE104
REGULATORY STRATEGY FOR INVESTIGATIONAL NEW DRUG
(IND) APPLICATION AND NEW DRUG APPLICATION SUBMISSIONS
FOR TDDS
Standard irritation and sensitization studies
should be performed with the patch itself in animals/humans.
Negotiate the timing and implementation of the
toxicology requirements.
The dermatology division at FDA should review
dermal aspects of the IND and New drug Application(NDA).
Primary review should occur at the division that
handles the indication under study.
Dose ranging studies be required in Phase 2.
Single Phase 3 study could be negotiated.
105. 06/04/16SAGAR KISHOR SAVALE105
Drug Trade name
Type of
transdermal
patch
Manufacturer Indication
Fentanyl Duragesic Reservoir
Alza / Janssen
Pharmaceuticals
Analgesic
Nitroglycerine
Deponit
Minitran
Nitro disc
Nitro- dur
Transderm-Nitro
Drug in adhesive
Drug in adhesive
Micro reservoir
Matrix
Reservoir
Schwarz Pharma
3M
Pharmaceuticals
Searle, USA
Key
Pharmaceuticals
Alza/Novartis
Angina Pectoris
Scopolamine Transderm- Scop
Membrane matrix
hybrid type
Alza/Novartis Motion sickness
106. References:-
Chein, Y W, 1992, Novel Drug Delivery System, 2nd
edition, vol-14, Marcel Dekker
Inc, New York, pp- 301-314.
Banker, G S, & Rhodes, C T, 2002, Modern Pharmaceutics, 4th
edition, vol-121, Marcel
Dekker Inc, New York, pp. 187-192.
Hsieh, D S, 1994, Drug Permeation Enhancement, theory and application, vol-62, Marcel
Dekker Inc, New York, pp. 3-23.
Roberts, M S, & Walters, K A, 1998, Dermal Absorption and Toxicity Assessment, vol-91,
Marcel Dekker Inc, New York, pp 297-309 371-375.
Walters, K A, 2002, Dermatological and Transdermal Formulation,vol-119, Marcel Dekker
Inc, New York, pp 1-14 337-339.
Brahmankar, D M & Jaiswal, S B, 2005, Biopharmaceutics and Pharmacokinetics A Treatise,
Vallabh prakashan, Delhi, pp-365-369.
06/04/16SAGAR KISHOR SAVALE106
107. Sachan, N.K, et al, 2009, Transdermal Approaches in drug delivery, Der Pharmacia
Lettre, pp 4-47.
Heather, A E, 2005, Transdermal Drug Delivery: Penetration Enhancement
Techniques, Current Drug delivery, vol-2, pp 23-33.
Kandavilli, S, et al, 2002, Polymers used in Transdermal Drug delivery System,
Pharmaceutical Technologies, pp 62-80.
Pathan, B I, et al, 2009, Chemical Penetration Enhancers for Transdermal Drug delivery
System, Tropical Journal of Pharmaceutical Research, pp 173-179.
Cross, S E, et al, 2004, Physical Enhancement of Transdermal Drug Application: Is
Delivery Technology Keeping up with Pharmaceutical Development?, Current Drug
Delivery, pp 81-92.
Aggarwal, G, 2009, Development, Fabrication and Evaluation of Transdermal Drug
Delivery System - A Review, Pharmainfo, Vol. 7 Issue 5.
06/04/16SAGAR KISHOR SAVALE107